Stock Analysis Report

Header cover image

Executive Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. More Details

Snowflake Analysis

Established dividend payer and good value.

Similar Companies

Share Price & News

How has Pfizer's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PFE's weekly volatility (5%) has been stable over the past year.

Market Performance

7 Day Return




US Pharmaceuticals


US Market

1 Year Return




US Pharmaceuticals


US Market

Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.

Return vs Market: PFE underperformed the US Market which returned 21% over the past year.

Shareholder returns

7 Day-0.8%1.6%0.6%
30 Day-5.1%4.4%4.2%
90 Day-3.2%8.2%12.4%
1 Year-0.6%-9.5%6.4%2.8%23.7%21.0%
3 Year17.3%-0.6%23.7%14.0%47.4%37.6%
5 Year53.0%20.2%53.2%35.0%131.6%105.9%

Long-Term Price Volatility Vs. Market

How volatile is Pfizer's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Pfizer undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: PFE ($36.75) is trading below our estimate of fair value ($90.64)

Significantly Below Fair Value: PFE is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: PFE is good value based on its PE Ratio (23.5x) compared to the US Pharmaceuticals industry average (24.2x).

PE vs Market: PFE is poor value based on its PE Ratio (23.5x) compared to the US market (21.3x).

Price to Earnings Growth Ratio

PEG Ratio: PFE is poor value based on its PEG Ratio (44.6x)

Price to Book Ratio

PB vs Industry: PFE is good value based on its PB Ratio (3.1x) compared to the US Pharmaceuticals industry average (4.3x).

Next Steps

Future Growth

How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PFE's forecast earnings growth (0.5% per year) is below the savings rate (2%).

Earnings vs Market: PFE's earnings (0.5% per year) are forecast to grow slower than the US market (21.6% per year).

High Growth Earnings: PFE's earnings are forecast to grow, but not significantly.

Revenue vs Market: PFE's revenue (0.8% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: PFE's revenue (0.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (22%)

Next Steps

Past Performance

How has Pfizer performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PFE has a large one-off loss of $6.4B impacting its September 27 2020 financial results.

Growing Profit Margin: PFE's current net profit margins (17.9%) are lower than last year (30.5%).

Past Earnings Growth Analysis

Earnings Trend: PFE's earnings have grown by 14% per year over the past 5 years.

Accelerating Growth: PFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PFE had negative earnings growth (-46.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.8%).

Return on Equity

High ROE: PFE's Return on Equity (13.3%) is considered low.

Next Steps

Financial Health

How is Pfizer's financial position?

Financial Position Analysis

Short Term Liabilities: PFE's short term assets ($47.7B) exceed its short term liabilities ($34.2B).

Long Term Liabilities: PFE's short term assets ($47.7B) do not cover its long term liabilities ($79.3B).

Debt to Equity History and Analysis

Debt Level: PFE's debt to equity ratio (94.4%) is considered high.

Reducing Debt: PFE's debt to equity ratio has increased from 58.2% to 94.4% over the past 5 years.

Debt Coverage: PFE's debt is well covered by operating cash flow (20.3%).

Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (11.4x coverage).

Balance Sheet

Next Steps


What is Pfizer current dividend yield, its reliability and sustainability?


Current Dividend Yield

Upcoming Dividend Payment

Dividend Yield vs Market

Notable Dividend: PFE's dividend (4.24%) is higher than the bottom 25% of dividend payers in the US market (1.38%).

High Dividend: PFE's dividend (4.24%) is in the top 25% of dividend payers in the US market (3.84%)

Stability and Growth of Payments

Stable Dividend: PFE's dividends per share have been stable in the past 10 years.

Growing Dividend: PFE's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (95.8%), PFE's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: PFE's dividends in 3 years are forecast to be covered by earnings (53.8% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Albert Bourla (58 yo)





Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer ...

CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD17.93M) is above average for companies of similar size in the US market ($USD10.54M).

Compensation vs Earnings: Albert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

Leadership Team

Albert Bourla
Chairman of the Board & CEO2yrsUS$17.93m0.0015%
$ 3.0m
John Young
Group President & Chief Business Officer8.58yrsUS$8.96m0.0076%
$ 15.4m
Frank D'Amelio
CFO & Executive VP of Global Supply13.33yrsUS$11.08m0.0076%
$ 15.6m
Mikael Dolsten
Chief Scientific Officer and President of Worldwide Research2yrsUS$9.60mno data
Jennifer Damico
Senior VP0.83yrno data0.00014%
$ 286.0k
Lidia Fonseca
Executive VP and Chief Digital & Technology Officer2yrsno data0.00078%
$ 1.6m
Charles Triano
Senior Vice President of Investor Relations12.58yrsno datano data
Douglas Lankler
Executive VP & General Counsel7.08yrsno data0.0014%
$ 2.9m
Rady Johnson
Executive VP and Chief Compliance7.08yrsno data0.0012%
$ 2.5m
Alexander MacKenzie
Chief Development Officer & Executive VP of Global Product Development4.83yrsno data0.0022%
$ 4.4m
Payal Becher
Executive VP & Chief Human Resources Officerno datano data0.00040%
$ 817.1k
Andreas Penk
MD & Regional President of Oncologyno datano datano data


Average Tenure


Average Age

Experienced Management: PFE's management team is seasoned and experienced (6 years average tenure).

Board Members

Albert Bourla
Chairman of the Board & CEO2yrsUS$17.93m0.0015%
$ 3.0m
Shantanu Narayen
Lead Independent Director2.75yrsUS$400.00kno data
Ronald Blaylock
Independent Director3.92yrsUS$350.00k0.00023%
$ 469.8k
Suzanne Nora Johnson
Independent Director13.33yrsUS$380.00k0.00018%
$ 367.7k
James Smith
Independent Director6.58yrsUS$380.00k0.000060%
$ 122.6k
Charles Hagel
Member of Emerging Markets Advisory Boardno datano datano data
Susan Hockfield
Independent Director0.83yrno datano data
Daniel Littman
Independent Director2.83yrsUS$344.70kno data
James Robert Quincey
Independent Director0.92yrno datano data
Scott Gottlieb
Independent Director1.58yrsUS$231.62k0.000070%
$ 143.0k
Joseph Echevarria
Independent Director5.58yrsUS$365.00kno data
Helen Hobbs
Independent Director9.08yrsUS$383.60kno data


Average Tenure


Average Age

Experienced Board: PFE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Pfizer Inc.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Pfizer Inc.
  • Ticker: PFE
  • Exchange: NYSE
  • Founded: 1849
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$204.271b
  • Shares outstanding: 5.56b
  • Website: https://www.pfizer.com

Number of Employees


  • Pfizer Inc.
  • 235 East 42nd Street
  • New York
  • New York
  • 10017
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PFENYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
PFE *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
0Q1NLSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
PFEOM (OMX Nordic Exchange Stockholm)YesCommon StockSESEKJan 1968
PFEDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
PFEXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1968
PFEBVC (Bolsa de Valores de Colombia)YesCommon StockCOCOPJan 1968
PFESBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBSEKJan 1968
PFESNSE (Santiago Stock Exchange)YesCommon StockCLUSDJan 1968
PF-UETLX (Eurotlx)YesCommon StockITEURJan 1968
PFEWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1968
PFEBVL (Bolsa de Valores de Lima)YesCommon StockPEUSDJan 1968
US_PFE_KAS (Kazakhstan Stock Exchange)YesCommon StockKZKZTJan 1968
PFEBASE (Buenos Aires Stock Exchange)CEDEAR EACH 2 REP 1 ORD USD0.05ARARSSep 2000
PFIZ34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 4 REP 1 COMBRBRLMay 2011
PFE WINYSE (New York Stock Exchange)COMUSUSDNov 2020


Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Ch...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/15 01:02
End of Day Share Price2021/01/14 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.